Azitra (AZTR) Current Deferred Revenue (2022 - 2023)
Azitra (AZTR) posted Current Deferred Revenue of $310700.0 for Q2 2023, up 99.17% on a QoQ basis from $156000.0 in Q4 2022.
Azitra (AZTR) Current Deferred Revenue (2022 - 2023) Analysis & Trends
Azitra's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $310700.0 for Q2 2023.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $310700.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $310700.0 (changed N/A YoY) and the FY2022 annual result came in at $156000.0, changed N/A from the prior year.
- Current Deferred Revenue was $310700.0 for Q2 2023 at Azitra, up from $156000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $310700.0 in Q2 2023 and bottomed at $156000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 310,700.00 |
| Dec 31, 2022 | 156,000.00 |